MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eclinm.2026.103867

Медицинская библиотека · EClinicalMedicine · 2026

Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study.

Waldrop Megan A, Escudero Roberto Bernardo, Yang Lina, Camarata Rebekah A, Branic Emily C, Mehl Lesa, Ilić Andreja, Connolly Anne M

СтатьяПеревод в очереди

Аннотация

BACKGROUND

LT-001 evaluated long-term safety/efficacy of onasemnogene abeparvovec (OA) for spinal muscular atrophy (SMA) patients from START (N = 15; NCT02122952).

METHODS

Reported is an interim analysis (5-year totalling up to 10-years post-dose) of long-term follow-up data from START (phase 1, open-label, single-arm, dose-escalation; 2-year follow-up [Nationwide Children's Hospital, Columbus, Ohio] [first patient dosed: May 5, 2014]). Patients (symptomatic SMA type 1, biallelic SMN1 mutations/deletions, two SMN2 copies; full analysis set) received single intravenous OA dose (low [6·7 × 1013 vg/kg] or proposed therapeutic dose [equivalent to 1·1 × 1014 vg/kg]). Safety (primary outcome) and efficacy (alive and independent of permanent ventilatory support [post hoc]) were assessed (NCT03421977 [September 21, 2017-September 17, 2018]).

FINDINGS: The LT-001 study was initiated on September 21, 2017, and the last patient was enrolled on September 17, 2018. As of July 1, 2024, 13 START patients enrolled in LT-001 (n = 3/13, low-dose; n = 10/13, therapeutic-dose). Mean (SD); min-max age at dosing was 6·3 (0·7); 5·8-7·1 months (low-dose) and 2·8 (1·5); 0·9-5·6 months (therapeutic-dose). Mean (SD); min-max follow-up duration was 9·9 (0·2); 9·8-10·1 years (low-dose) and 8·3 (1·1); 6·8-9·6 years (therapeutic-dose). Most patients (≥70%) received nusinersen/risdiplam post-dosing. Serious adverse events (n = 11/13; 85%) were most frequently acute respiratory failure, dehydration, and pneumonia (none led to study discontinuation or death). Six adverse events (AEs) of special interest (n = 4/13; 31%) included transient thrombocytopenia, cardiac AEs, and new incidence of neurologic disorders (unrelated to treatment). All (n = 13/13) were alive at last visit (n = 5 therapeutic-dose) or data cutoff (n = 8 ongoing). The majority (n = 12/13) were free of permanent ventilation.

INTERPRETATION: OA demonstrated a favourable benefit-risk profile and efficacy up to 10 years for START/LT-001 patients, though there are limitations (descriptive analyses, small population, add-on therapy, lack of comparator). Further long-term research may build on phase 3/4 study findings with OA for SMA patients.

FUNDING: Novartis Pharma AG.

Для цитирования: Waldrop Megan A, Escudero Roberto Bernardo, Yang Lina, Camarata Rebekah A, Branic Emily C, Mehl Lesa, Ilić Andreja, Connolly Anne M. Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study.. EClinicalMedicine. 2026. DOI: 10.1016/j.eclinm.2026.103867.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.